H.Lundbeck Korea eye CNS market in Korea

H.Lundbeck A/S, a renowned CNS drug maker in the world, has finally entered the Korean market with a firm strategy to expand their presence in the domestic CNS market within the next three years under strategic alliances with Whanin Pharm.

In his press interview, president Ole Steen Antonsen of H.Lundbeck Korea said, " the domestic entry of Cipram (citalopram), a selective serotonin reuptak...